ClinicalTrials.gg
CompletedNCT03361358Updated Mar 16, 2020

Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma

An observational study in Advanced Solid Tumors and Lymphoma, sponsored by Agios Pharmaceuticals, Inc.. Completed at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-16.

Sponsored by Agios Pharmaceuticals, Inc. · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
44
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 1,910 studies in Lymphoma with a site in United States — 162 open to participants now, 289 under way, 15 of them phase 3. Lymphoma · United States.

Enrollment
113th of 160
44 · median 120
Started
2018
with 58 others
Observational
160 of 1,910
31 open now
Registered
1,503rd of 1,910
by date

Among the 1,910 studies in Lymphoma with a site in United States, this one is the 113th largest by enrollment of the 160 observational ones that give a count, is one of 59 that started in 2018, is one of 160 observational ones, and was the 1,503rd registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 435 are open to participants now.

Browse Lymphoma studies →

Open to participants now

162 of the 1,910 studies in Lymphoma with a site in United States are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 347 Lymphoma studies recruiting now, 228 (66%) set no upper age limit and 78 (22%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,910 studies in Lymphoma with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to identify subjects with advanced solid tumors or lymphoma in which the methylthioadenosine phosphorylase (MTAP) protein has been lost.

Read the detailed description

Study AG270-PS-001 is a pre-screening study to identify subjects with advanced solid tumors or lymphoma in which the MTAP protein has been lost. Subjects whose tumor tissue has lost the MTAP protein may be considered for future enrollment into a Phase 1 clinical study of an experimental drug, AG-270, that is designed to inhibit the growth of tumors lacking this protein.

Identification of the loss of MTAP will rely solely on the evaluation of archival tumor tissue samples by IHC. This study is therefore non-interventional

03

Conditions studied

  • Advanced Solid Tumors
  • Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects appropriate for this study will be identified by the Investigators at the study sites based on their clinical judgment. This study may be conducted in subjects who are not currently eligible for an experimental therapy, recognizing that determination of the tumor's MTAP status could be useful in making future decisions about options for treatment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be ≥18 years of age.
  2. Have a confirmed diagnosis of an advanced solid tumor (other than a primary CNS ) or lymphoma.
  3. Have that can be provided for assessment of MTAP deletion status.
  4. Have given written to participate in this study.

Exclusion criteria

Exclusion Criteria:

  1. Have a primary CNS (eg, GBM).
  2. Have a medical or psychological condition deemed by the Investigator likely to interfere with the subject's ability to give or participate in the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
44 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Determination of MTAP status in tumors

    Number of tumor tissue samples found to have or not have MTAP deletion, as assessed by IHC

    Time frame: From initiation of the Pre-Screen study until the Phase 1 study of AG-270 is activated at each study site, up to 9 months

07

Study locations

3 sites
  • Boston, MA
    Boston, Massachusetts 02114, United States
  • Nashville, TN
    Nashville, Tennessee 37203, United States
  • Barcelona, Spain
    Barcelona, 08035, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Sep 2019, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2017
First posted
Dec 4, 2017
StartActual
Mar 1, 2018
Primary completionActual
Sep 30, 2019
CompletionActual
Sep 30, 2019
Last update
Mar 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03361358
Responsible party
Sponsor
First posted
Dec 4, 2017
Start date
Mar 1, 2018
Primary completion
Sep 30, 2019
Completion
Sep 30, 2019
Last update
Mar 16, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion